SCHEMBL4313359

SCHEMBL4313359

CN1CCN(c2ccc(N)c(/C=C/c3n[nH]c4ccccc34)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 4/20 0.52
FLT1 P17948 2/20 0.52
JAK2 O60674 1/20 0.48
PDGFRB P09619 3/20 0.43
KDR P35968 3/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RECQL P46063 1/20 0.43
PTK2B Q14289 1/20 0.43
HTR6 P50406 7/20 0.42
DRD2 P14416 2/20 0.42
HTR7 P34969 2/20 0.42
HTR2B P41595 2/20 0.42
AURKB Q96GD4 2/20 0.42
HTR2C P28335 1/20 0.42
AURKA O14965 1/20 0.42
HRH4 Q9H3N8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313362 1.00 FGFR1 (0.52) FGFR1FLT1JAK2PDGFRBKDR
SCHEMBL4326946 0.87 FGFR1 (0.53) FGFR1FLT1JAK2PDGFRBKDR
SCHEMBL4326947 0.87 FGFR1 (0.53) FGFR1FLT1JAK2PDGFRBKDR
SCHEMBL4317835 0.83 HTR6 (0.39) FGFR1FLT1JAK2PDGFRBKDR
SCHEMBL4317837 0.83 HTR6 (0.39) FGFR1FLT1JAK2PDGFRBKDR
SCHEMBL4320632 0.83 MAPT (0.48) FGFR1FLT1MAPTMAPK1HTT
SCHEMBL4320637 0.83 MAPT (0.48) FGFR1FLT1MAPTMAPK1HTT
SCHEMBL4327057 0.79 FGFR1 (0.42) FGFR1FLT1JAK2PDGFRBKDR
SCHEMBL4327051 0.79 FGFR1 (0.42) FGFR1FLT1JAK2PDGFRBKDR
SCHEMBL4317941 0.79 FGFR1 (0.42) FGFR1FLT1JAK2DRD2AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 FGFR1 18/4885FLT1 81/4885JAK2 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.